



Contact | Jennie Wilde, PR Consultant
p | +44 (0)20 38148445
e | jennie@carverwilde.com

Beckman Coulter Life Sciences Collaborates with IncellDx to Highlight Oncology Assays Partnered with Flow Cytometry

Single Cell Analysis Leverages Precision of Flow Cytometry Technology

INDIANAPOLIS, USA – (November 20, 2019) – Beckman Coulter Life Sciences and IncellDx, Inc. have announced a partnership which combines the latest in molecular testing with the precision of high throughput flow cytometry. IncellDx has four new cancer detection reagents which were developed on Beckman Coulter’s instruments. The two companies will partner to create awareness for the assays on the cytometry platform to customers in Europe.*

The four IncellDx assays relate to lung and bladder cancers as well as HPV cancers affecting the head, neck and cervix. The kits pair the single cell functionality of flow cytometry with molecular analysis to get information on mRNA and protein expression as well as cell cycle and/or proliferation.

“The new partnership brings the power of multi-parameter flow cytometry to molecular testing, improving workflow while delivering sensitive and highly reliable cell identification,” said Dr. Mario Kokschi, Vice President and General Manager, Beckman Coulter Life Sciences Cytometry Business Unit. “In addition, the oncology menu of IncellDx adds a new dimension to Beckman Coulter instruments, such as the CytoFLEX Series*, which positions our technology at the forefront of clinical research.”

IncellDx is an entrepreneurial company based in California, USA, with a global reputation for its cancer detection assays used in clinical research.

-more-

Beckman Coulter Life Sciences Collaborates with IncellDx to Highlight Oncology Assays Partnered with Flow Cytometry
Page 2 of 2

Bruce Patterson MD, the CEO and Founder of IncellDx, commented: “In cancer research it is essential to carry out quantification at the single cell level. Adding our single cell, simultaneous protein, mRNA, and cell cycle/DNA content assays to the exceptional technology behind Beckman Coulter Life Sciences flow cytometry instruments will open up a new era in understanding cancer biology.”

About IncellDx

IncellDx is a molecular diagnostics company dedicated to revolutionizing healthcare one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, the company’s focus is on critical life threatening diseases in the areas of cancer, specifically cervical, head and neck, lung, bladder, breast and prostate cancers. For more information, please visit <http://incelldx.com/>

About Beckman Coulter Life Sciences

Beckman Coulter Life Sciences develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. For more than 75 years, our products have been making a difference in people’s lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs. For more information, visit www.beckman.com. Follow Beckman Coulter Life Sciences on Twitter @BCILifeSciences; Facebook: <https://www.facebook.com/BCILifeSciences> and LinkedIn: <https://www.linkedin.com/company/beckman-coulter-ls/>

** For research Use Only. Not Intended for Diagnostic Purposes.*

###

Note to Editors

Three images provided: Logos for IncellDx and Beckman Coulter Life Sciences; assay pack image for BCLS and IncellDx News Release ‘Beckman Coulter Life Sciences Collaborates with IncellDx to Highlight Oncology Assays Partnered with Flow Cytometry’.